sentence
stringlengths 27
1.01k
| drug1
stringlengths 2
46
| drug2
stringlengths 2
63
| relation
stringclasses 5
values | source_file
stringclasses 566
values | sentence_id
stringlengths 17
21
| pair_id
stringlengths 20
26
|
|---|---|---|---|---|---|---|
[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of phentolamine.
|
picrotoxin
|
phenibut
|
EFFECT
|
2857099.xml
|
DDI-MedLine.d27.s0
|
DDI-MedLine.d27.s0.p2
|
- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
|
acetophenazine
|
Tindal
|
NONE
|
Sulfapyridine_ddi.xml
|
DDI-DrugBank.d179.s21
|
DDI-DrugBank.d179.s21.p24
|
Coadministration of NIZORAL Tablets with midazolam or triazolam has resulted in elevated plasma concentrations of the latter two drugs.
|
midazolam
|
triazolam
|
NONE
|
Ketoconazole_ddi.xml
|
DDI-DrugBank.d458.s12
|
DDI-DrugBank.d458.s12.p2
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
EQUETROTM
|
clozapine
|
MECHANISM
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p8
|
Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
|
antihistamines
|
monoamine oxidase (MAO) inhibitors
|
NONE
|
Brompheniramine_ddi.xml
|
DDI-DrugBank.d192.s0
|
DDI-DrugBank.d192.s0.p30
|
DIDREX should not be used concomitantly with other CNS stimulants.
|
DIDREX
|
CNS stimulants
|
ADVISE
|
Benzphetamine_ddi.xml
|
DDI-DrugBank.d477.s1
|
DDI-DrugBank.d477.s1.p0
|
The MPTP-induced neuronal damage produced a tolerance to the disruptive effects of amphetamine and a supersensitivity to the disruptive effects of apomorphine in rats responding in a schedule controlled paradigm.
|
MPTP
|
amphetamine
|
EFFECT
|
3871245.xml
|
DDI-MedLine.d73.s3
|
DDI-MedLine.d73.s3.p0
|
Amphotericin B or Corticosteroids or Corticotropin (ACTH)
|
Amphotericin B
|
Corticosteroids
|
NONE
|
Hydroflumethiazide_ddi.xml
|
DDI-DrugBank.d17.s9
|
DDI-DrugBank.d17.s9.p0
|
Paroxetine produced only minor changes in the levels of clozapine and its metabolites.
|
Paroxetine
|
clozapine
|
MECHANISM
|
Clozapine_ddi.xml
|
DDI-DrugBank.d480.s21
|
DDI-DrugBank.d480.s21.p0
|
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .
|
apomorphine
|
palonosetron
|
ADVISE
|
Apomorphine_ddi.xml
|
DDI-DrugBank.d357.s0
|
DDI-DrugBank.d357.s0.p28
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
ethosuximide
|
haloperidol
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p603
|
Beta blockers may exacerbate the hypertensive response seen with clonidine withdrawl.
|
Beta blockers
|
clonidine
|
EFFECT
|
Clonidine_ddi.xml
|
DDI-DrugBank.d495.s6
|
DDI-DrugBank.d495.s6.p0
|
Isoproterenol hydrochloride injection and epinephrine should not be administered simultaneously because both drugs are direct cardiac stimulants and their combined effects may induce serious arrhythmias.
|
Isoproterenol hydrochloride
|
epinephrine
|
ADVISE
|
Isoproterenol_ddi.xml
|
DDI-DrugBank.d55.s0
|
DDI-DrugBank.d55.s0.p0
|
Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.
|
succinylcholine
|
Coly-Mycin M
|
EFFECT
|
Colistimethate_ddi.xml
|
DDI-DrugBank.d250.s2
|
DDI-DrugBank.d250.s2.p14
|
d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;
|
d-amphetamine
|
tricyclics
|
MECHANISM
|
Dextroamphetamine_ddi.xml
|
DDI-DrugBank.d236.s8
|
DDI-DrugBank.d236.s8.p2
|
Cyclosporine, Digoxin, Methotrexate Lodine, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, digoxin, methotrexate, and increased toxicity.
|
NSAIDs
|
digoxin
|
MECHANISM
|
Etodolac_ddi.xml
|
DDI-DrugBank.d219.s7
|
DDI-DrugBank.d219.s7.p5
|
The vasodilating effects of isosorbide dinitrate may be additive with those of other vasodilators.
|
isosorbide dinitrate
|
vasodilators
|
EFFECT
|
Isosorbide Dinitrate_ddi.xml
|
DDI-DrugBank.d465.s0
|
DDI-DrugBank.d465.s0.p0
|
Anticonvulsants (carbamazepine, felbamate, phenobarbital, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.
|
phenobarbital
|
phenytoin
|
NONE
|
Ethynodiol Diacetate_ddi.xml
|
DDI-DrugBank.d485.s12
|
DDI-DrugBank.d485.s12.p18
|
Also, due to the potential for additive effects such as bradycardia and AV block, caution is warranted in patients receiving clonidine with agents known to affect sinus node function or AV nodal conduction (e.g., digitalis, calcium channel blockers, and beta-blockers.)
|
clonidine
|
digitalis
|
ADVISE
|
Clonidine_ddi.xml
|
DDI-DrugBank.d495.s7
|
DDI-DrugBank.d495.s7.p0
|
Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
|
bupropion
|
desipramine
|
ADVISE
|
Bupropion_ddi.xml
|
DDI-DrugBank.d5.s17
|
DDI-DrugBank.d5.s17.p3
|
- Perhexiline hydrogen maleate or MAO-inhibitors (with hepatotoxic potential) must not be administered together with Bezalip or Bezalip retard.
|
MAO-inhibitors
|
Bezalip retard
|
ADVISE
|
Bezafibrate_ddi.xml
|
DDI-DrugBank.d291.s11
|
DDI-DrugBank.d291.s11.p4
|
Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).
|
psychoactive drugs
|
barbiturates
|
NONE
|
Nabilone_ddi.xml
|
DDI-DrugBank.d552.s0
|
DDI-DrugBank.d552.s0.p7
|
Short-term pharmacokinetic studies have demonstrated that concomitant administration of warfarin and Lodine (etodolac capsules and tablets) results in reduced protein binding of warfarin, but there was no change in the clearance of free warfarin.
|
warfarin
|
etodolac
|
MECHANISM
|
Etodolac_ddi.xml
|
DDI-DrugBank.d219.s23
|
DDI-DrugBank.d219.s23.p1
|
Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.
|
antidepressants
|
nicotine
|
NONE
|
Chlorotrianisene_ddi.xml
|
DDI-DrugBank.d446.s0
|
DDI-DrugBank.d446.s0.p21
|
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.
|
ORENCIA
|
azathioprine
|
NONE
|
Abatacept_ddi.xml
|
DDI-DrugBank.d297.s2
|
DDI-DrugBank.d297.s2.p4
|
- Phenytoin (e.g., Dilantin) Use of phenytoin with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of phenytoin
|
phenytoin
|
sulfapyridine
|
EFFECT
|
Sulfapyridine_ddi.xml
|
DDI-DrugBank.d179.s40
|
DDI-DrugBank.d179.s40.p7
|
Drugs that may have their plasma concentration altered by Gleevec Gleevec increases the mean cmax and AUC of simvastatin (CYP3A4 substrate) 2- and 3.5-fold, respectively, suggesting an inhibition of the CYP3A4 by Gleevec.
|
Gleevec
|
simvastatin
|
MECHANISM
|
Imatinib_ddi.xml
|
DDI-DrugBank.d115.s8
|
DDI-DrugBank.d115.s8.p3
|
Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).
|
amphotericin
|
zalcitabine
|
MECHANISM
|
Zalcitabine_ddi.xml
|
DDI-DrugBank.d263.s18
|
DDI-DrugBank.d263.s18.p21
|
The antihypertensive effects of methyldopa, mecamylamine, reserpine, and veratrum alkaloids may be reduced by sympathomimetics.
|
veratrum alkaloids
|
sympathomimetics
|
EFFECT
|
Azatadine_ddi.xml
|
DDI-DrugBank.d448.s3
|
DDI-DrugBank.d448.s3.p9
|
Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).
|
Nabilone
|
barbiturates
|
ADVISE
|
Nabilone_ddi.xml
|
DDI-DrugBank.d552.s0
|
DDI-DrugBank.d552.s0.p3
|
Beta-blockers, clonidine, lithium salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of insulin.
|
Beta-blockers
|
insulin
|
EFFECT
|
Insulin Glargine recombinant_ddi.xml
|
DDI-DrugBank.d527.s3
|
DDI-DrugBank.d527.s3.p3
|
As with some other nondepolarizing neuromuscular blocking agents, the time of onset of neuromuscular block induced by NUROMAX is lengthened and the duration of block is shortened in patients receiving phenytoin or carbamazepine.
|
nondepolarizing neuromuscular blocking agents
|
phenytoin
|
EFFECT
|
Doxacurium chloride_ddi.xml
|
DDI-DrugBank.d267.s6
|
DDI-DrugBank.d267.s6.p1
|
Effects of Erythromycin on Felbatol The coadministration of erythromycin (1000 mg/day) for 10 days did not alter the pharmacokinetic parameters of Cmax, Cmin, AUC, CI/kg or tmax at felbamate daily doses of 3000 or 3600 mg/day in 10 otherwise healthy subjects with epilepsy.
|
Erythromycin
|
erythromycin
|
NONE
|
Felbamate_ddi.xml
|
DDI-DrugBank.d434.s36
|
DDI-DrugBank.d434.s36.p1
|
Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and FROVA within 24 hours of each other should be avoided (see a href= frova_od.htm#CI CONTRAINDICATIONS).
|
ergot-type medications
|
FROVA
|
ADVISE
|
Frovatriptan_ddi.xml
|
DDI-DrugBank.d426.s1
|
DDI-DrugBank.d426.s1.p6
|
Propranolol: May decrease aspirins anti-inflammatory action by competing for the same receptors.
|
Propranolol
|
aspirins
|
EFFECT
|
Aspirin_ddi.xml
|
DDI-DrugBank.d443.s8
|
DDI-DrugBank.d443.s8.p0
|
Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).
|
barbiturates
|
estrogens
|
NONE
|
Butabarbital_ddi.xml
|
DDI-DrugBank.d184.s0
|
DDI-DrugBank.d184.s0.p67
|
Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies (phenytoin, valproate, oral contraceptive, digoxin, warfarin, probenecid) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients.
|
digoxin
|
warfarin
|
NONE
|
Levetiracetam_ddi.xml
|
DDI-DrugBank.d212.s5
|
DDI-DrugBank.d212.s5.p12
|
Furosemide: Clinical studies, as well as random observations, have shown that ibuprofen can reduce the natriuretic effect of furosemide and thiazides in some patients.
|
ibuprofen
|
thiazides
|
EFFECT
|
Ibuprofen_ddi.xml
|
DDI-DrugBank.d415.s9
|
DDI-DrugBank.d415.s9.p4
|
Anticoagulants: There have been reports of increased anticoagulant effects when erythromycin and oral anticoagulants were used concomitantly.
|
erythromycin
|
anticoagulants
|
EFFECT
|
Dirithromycin_ddi.xml
|
DDI-DrugBank.d522.s21
|
DDI-DrugBank.d522.s21.p2
|
Naproxen and other NSAIDs can reduce the antihypertensive effect of propranolol and other beta-blockers.
|
NSAIDs
|
propranolol
|
EFFECT
|
Naproxen_ddi.xml
|
DDI-DrugBank.d85.s9
|
DDI-DrugBank.d85.s9.p3
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
chlorpropamide
|
triclofos sodium
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p491
|
Intestinal adsorbents (e. g., charcoal) and digestive enzyme preparations containing carbohydrate-splitting enzymes (e. g., amylase, pancreatin) may reduce the effect of Acarbose and should not be taken concomitantly.
|
amylase
|
Acarbose
|
MECHANISM
|
Acarbose_ddi.xml
|
DDI-DrugBank.d536.s4
|
DDI-DrugBank.d536.s4.p13
|
When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.
|
azithromycin
|
midazolam
|
MECHANISM
|
Azithromycin_ddi.xml
|
DDI-DrugBank.d53.s7
|
DDI-DrugBank.d53.s7.p7
|
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, digoxin, warfarin, isosorbide mononitrate, carvedilol, ethanol or itraconazole.
|
felodipine
|
digoxin
|
NONE
|
Levosimendan_ddi.xml
|
DDI-DrugBank.d189.s0
|
DDI-DrugBank.d189.s0.p24
|
In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or pharmacokinetics of digoxin.
|
irbesartan
|
warfarin
|
NONE
|
Irbesartan_ddi.xml
|
DDI-DrugBank.d27.s4
|
DDI-DrugBank.d27.s4.p12
|
Acetaminophen: May increase plasma concentration of synthetic estrogens, possibly by inhibiting conjugation.
|
Acetaminophen
|
synthetic estrogens
|
MECHANISM
|
Ethynodiol Diacetate_ddi.xml
|
DDI-DrugBank.d485.s2
|
DDI-DrugBank.d485.s2.p0
|
Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
|
anticoagulant
|
antihistamines
|
EFFECT
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s29
|
DDI-DrugBank.d64.s29.p3
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
bupropion
|
zonisamide
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p214
|
Amprenavir plus rifabutin was poorly tolerated, and 5 of 11 subjects discontinued therapy.
|
Amprenavir
|
rifabutin
|
EFFECT
|
11158747.xml
|
DDI-MedLine.d3.s12
|
DDI-MedLine.d3.s12.p0
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
delavirdine
|
lamotrigine
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p450
|
Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
|
EQUETROTM
|
isoniazid
|
MECHANISM
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s4
|
DDI-DrugBank.d94.s4.p11
|
Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.
|
Cholestyramine
|
thiazide diuretics
|
MECHANISM
|
Cholestyramine_ddi.xml
|
DDI-DrugBank.d566.s0
|
DDI-DrugBank.d566.s0.p3
|
Digoxin - In subjects who had received 21 days of 40 mg/day racemic citalopram, combined administration of citalopram and digoxin (single dose of 1 mg) did not significantly affect the pharmacokinetics of either citalopram or digoxin.
|
Digoxin
|
citalopram
|
NONE
|
Escitalopram_ddi.xml
|
DDI-DrugBank.d568.s9
|
DDI-DrugBank.d568.s9.p3
|
Propoxyphene: In cases of propoxyphene overdosage, amphetamine CNS stimulation is potentiated and fatal convulsions can occur.
|
propoxyphene
|
amphetamine
|
EFFECT
|
Dextroamphetamine_ddi.xml
|
DDI-DrugBank.d236.s27
|
DDI-DrugBank.d236.s27.p2
|
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital.
|
Innovar Vet
|
ouabain
|
EFFECT
|
1167743.xml
|
DDI-MedLine.d23.s1
|
DDI-MedLine.d23.s1.p16
|
Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
|
Probenecid
|
famotidine
|
MECHANISM
|
Cidofovir_ddi.xml
|
DDI-DrugBank.d260.s0
|
DDI-DrugBank.d260.s0.p24
|
Plasma exposure of diazepam (10 mg BID) was increased by 28% following administration of valdecoxib (40 mg BID) for 12 days, while plasma exposure of valdecoxib (40 mg BID) was not substantially increased following administration of diazepam (10 mg BID) for 12 days.
|
diazepam
|
diazepam
|
NONE
|
Valdecoxib_ddi.xml
|
DDI-DrugBank.d328.s48
|
DDI-DrugBank.d328.s48.p2
|
Omeprazole: The rate and extent of absorption of ciprofloxacin was bioequivalent when Proquin XR was given alone or when Proquin XR was given 2 hours after omeprazole at the dose that maximally suppresses gastric acid secretion.
|
Proquin XR
|
Proquin XR
|
NONE
|
Ciprofloxacin_ddi.xml
|
DDI-DrugBank.d123.s12
|
DDI-DrugBank.d123.s12.p7
|
When concomitant administration of ketoconazole with aripiprazole occurs, aripiprazole dose should be reduced to one-half of its normal dose.
|
ketoconazole
|
aripiprazole
|
ADVISE
|
Aripiprazole_ddi.xml
|
DDI-DrugBank.d509.s11
|
DDI-DrugBank.d509.s11.p0
|
Certain drugs including thiazides, corticosteroids, thyroid products, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.
|
corticosteroids
|
antidiabetic drugs
|
EFFECT
|
Nateglinide_ddi.xml
|
DDI-DrugBank.d460.s15
|
DDI-DrugBank.d460.s15.p8
|
The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.
|
norepinephrine
|
tricyclic antidepressants
|
EFFECT
|
Lidocaine_ddi.xml
|
DDI-DrugBank.d564.s0
|
DDI-DrugBank.d564.s0.p8
|
There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.
|
erythromycin
|
carbamazepine
|
INT
|
Erythromycin_ddi.xml
|
DDI-DrugBank.d397.s8
|
DDI-DrugBank.d397.s8.p0
|
Central Nervous System Depressants: The concomitant use of DURAGESIC (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
|
DURAGESIC
|
anesthetics
|
EFFECT
|
Fentanyl_ddi.xml
|
DDI-DrugBank.d170.s5
|
DDI-DrugBank.d170.s5.p19
|
Fenfluramine may increase slightly the effect of antihypertensive drugs, e.g., guanethidine, methyldopa, reserpine.
|
Fenfluramine
|
reserpine
|
EFFECT
|
Fenfluramine_ddi.xml
|
DDI-DrugBank.d104.s0
|
DDI-DrugBank.d104.s0.p3
|
Valproate: Tiagabine causes a slight decrease (about 10%) in steady-state valproate concentrations.
|
Tiagabine
|
valproate
|
MECHANISM
|
Tiagabine_ddi.xml
|
DDI-DrugBank.d277.s7
|
DDI-DrugBank.d277.s7.p2
|
Interaction on the antinociceptive effect between neurotensin and enkephalins or tuftsin.
|
neurotensin
|
tuftsin
|
EFFECT
|
6545985.xml
|
DDI-MedLine.d131.s0
|
DDI-MedLine.d131.s0.p1
|
ZEBETA should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently.
|
ZEBETA
|
diltiazem
|
ADVISE
|
Bisoprolol_ddi.xml
|
DDI-DrugBank.d476.s3
|
DDI-DrugBank.d476.s3.p5
|
Because lithium may enhance the serotonergic effects of escitalopram, caution should be exercised when LEXAPRO and lithium are coadministered.
|
escitalopram
|
LEXAPRO
|
NONE
|
Escitalopram_ddi.xml
|
DDI-DrugBank.d568.s12
|
DDI-DrugBank.d568.s12.p3
|
In common with other broad-spectrum antibiotics, AUGMENTIN XR may reduce the efficacy of oral contraceptives
|
AUGMENTIN XR
|
contraceptives
|
EFFECT
|
Clavulanate_ddi.xml
|
DDI-DrugBank.d419.s5
|
DDI-DrugBank.d419.s5.p2
|
Co-administration of CYP3A4 inhibitors (eg, ketoconazole, itraconazole, erythromycin, grapefruit juice, cimetidine) with felodipine may lead to several- fold increases in the plasma levels of felodipine, either due to an increase in bioavailability or due to a decrease in metabolism.
|
cimetidine
|
felodipine
|
NONE
|
Felodipine_ddi.xml
|
DDI-DrugBank.d316.s1
|
DDI-DrugBank.d316.s1.p13
|
Animal experience indicates that clorazepate dipotassium prolongs the sleeping time after hexobarbital or after ethyl alcohol, increases the inhibitory effects of chlorpromazine, but does not exhibit monoamine oxidase inhibition.
|
hexobarbital
|
chlorpromazine
|
NONE
|
Clorazepate_ddi.xml
|
DDI-DrugBank.d335.s1
|
DDI-DrugBank.d335.s1.p4
|
An encephalopathic syndrome (characterized by weakness, lethargy, fever, tremulousness and confusion, extrapyramidal symptoms, leukocytosis, elevated serum enzymes, BUN, and FBS) followed by irreversible brain damage has occurred in a few patients treated with lithium plus HALDOL.
|
lithium
|
HALDOL
|
EFFECT
|
Haloperidol_ddi.xml
|
DDI-DrugBank.d186.s0
|
DDI-DrugBank.d186.s0.p0
|
conversely, diethylpropion may interfere with antihypertensive drugs (i.e., guanethidine, a-methyldopa).
|
diethylpropion
|
a-methyldopa
|
INT
|
Diethylpropion_ddi.xml
|
DDI-DrugBank.d352.s3
|
DDI-DrugBank.d352.s3.p2
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
Tylenol
|
Astramorph
|
NONE
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p117
|
Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;magnesium salts;procainamide;and quinidine.
|
TRACRIUM
|
antibiotics
|
EFFECT
|
Atracurium_ddi.xml
|
DDI-DrugBank.d469.s7
|
DDI-DrugBank.d469.s7.p3
|
Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.
|
resin
|
phenobarbital
|
NONE
|
Cholestyramine_ddi.xml
|
DDI-DrugBank.d566.s0
|
DDI-DrugBank.d566.s0.p18
|
The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decrease by concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and adjustment of the dosage of imipramine may therefore be necessary.
|
barbiturates
|
imipramine
|
NONE
|
Imipramine_ddi.xml
|
DDI-DrugBank.d77.s5
|
DDI-DrugBank.d77.s5.p13
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
alcohol
|
salicylates
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p97
|
Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum.
|
ciprofloxacin
|
magnesium
|
MECHANISM
|
Didanosine_ddi.xml
|
DDI-DrugBank.d43.s8
|
DDI-DrugBank.d43.s8.p19
|
Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
|
androgens
|
perchlorate
|
NONE
|
Levothyroxine_ddi.xml
|
DDI-DrugBank.d411.s4
|
DDI-DrugBank.d411.s4.p97
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
Etonogestrel
|
Crixivan
|
INT
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p25
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
Topamax
|
Gris-PEG
|
NONE
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p431
|
When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered
|
CANCIDAS
|
nevirapine
|
ADVISE
|
Caspofungin_ddi.xml
|
DDI-DrugBank.d350.s14
|
DDI-DrugBank.d350.s14.p1
|
Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.
|
estrogens
|
progestins
|
NONE
|
Cholestyramine_ddi.xml
|
DDI-DrugBank.d566.s0
|
DDI-DrugBank.d566.s0.p75
|
Diuretic: Hydrochlorothiazide, given concomitantly with ketoprofen, produces a reduction in urinary potassium and chloride excretion compared to hydrochlorothiazide alone.
|
Hydrochlorothiazide
|
ketoprofen
|
EFFECT
|
Ketoprofen_ddi.xml
|
DDI-DrugBank.d499.s10
|
DDI-DrugBank.d499.s10.p3
|
Therophylline: A recent study has shown that concomitan administration of isoniazid and theophylline may cause elevated plasma levels of theophylline, and in some instances a slight decrease in the elimination of isoniazid.
|
isoniazid
|
theophylline
|
MECHANISM
|
Isoniazid_ddi.xml
|
DDI-DrugBank.d187.s11
|
DDI-DrugBank.d187.s11.p0
|
Therefore, increased monitoring of digoxin is recommended when initiating, adjusting, or discontinuing COREG.
|
digoxin
|
COREG
|
ADVISE
|
Carvedilol_ddi.xml
|
DDI-DrugBank.d269.s13
|
DDI-DrugBank.d269.s13.p0
|
Co-administration of BOTOX and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated.
|
BOTOX
|
curare-like compounds
|
ADVISE
|
Botulinum Toxin Type A_ddi.xml
|
DDI-DrugBank.d133.s0
|
DDI-DrugBank.d133.s0.p1
|
Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.
|
tetracyclines
|
anticoagulant
|
ADVISE
|
Doxycycline_ddi.xml
|
DDI-DrugBank.d500.s0
|
DDI-DrugBank.d500.s0.p0
|
Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.
|
butorphanol
|
Levo-Dromoran
|
ADVISE
|
Levorphanol_ddi.xml
|
DDI-DrugBank.d257.s6
|
DDI-DrugBank.d257.s6.p29
|
Fenfluramine may increase slightly the effect of antihypertensive drugs, e.g., guanethidine, methyldopa, reserpine.
|
Fenfluramine
|
antihypertensive drugs
|
EFFECT
|
Fenfluramine_ddi.xml
|
DDI-DrugBank.d104.s0
|
DDI-DrugBank.d104.s0.p0
|
If concomitant treatment with naratriptan and an SSRI is clinically warranted, appropriate observation of the patient is advised.
|
naratriptan
|
SSRI
|
ADVISE
|
Naratriptan_ddi.xml
|
DDI-DrugBank.d478.s5
|
DDI-DrugBank.d478.s5.p0
|
Cardiac Glycosides: In a study of young healthy male subjects no evidence of a direct pharmacokinetic captopril-digoxin interaction could be found.
|
Cardiac Glycosides
|
digoxin
|
NONE
|
Captopril_ddi.xml
|
DDI-DrugBank.d175.s21
|
DDI-DrugBank.d175.s21.p1
|
Anticonvulsants (carbamazepine, felbamate, phenobarbital, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.
|
phenytoin
|
progestins
|
MECHANISM
|
Ethynodiol Diacetate_ddi.xml
|
DDI-DrugBank.d485.s12
|
DDI-DrugBank.d485.s12.p24
|
Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
|
clarithromycin
|
itraconazole
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s4
|
DDI-DrugBank.d94.s4.p106
|
Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin, antipyrine, indomethacin, ibuprofen, phenytoin, propranolol, prednisone, diazepam, clarithromycin, or terfenadine in healthy subjects.
|
phenytoin
|
terfenadine
|
NONE
|
Lansoprazole_ddi.xml
|
DDI-DrugBank.d431.s1
|
DDI-DrugBank.d431.s1.p44
|
Colestipol: Plasma concentrations of atorvastatin decreased approximately 25% when colestipol and atorvastatin were coadministered.
|
colestipol
|
atorvastatin
|
MECHANISM
|
Atorvastatin_ddi.xml
|
DDI-DrugBank.d140.s4
|
DDI-DrugBank.d140.s4.p5
|
The effect of TORADOL on plasma lithium has not been studied, but cases of increased lithium plasma levels during TORADOL therapy have been reported.
|
TORADOL
|
lithium
|
NONE
|
Ketorolac_ddi.xml
|
DDI-DrugBank.d3.s12
|
DDI-DrugBank.d3.s12.p1
|
Therefore, when heparin sodium is given with dicumarol or warfarin sodium, a period of at least 5 hours after the last intravenous dose or 24 hours after the last subcutaneous dose should elapse before blood is drawn if a valid prothrombin time is to be obtained.
|
heparin sodium
|
warfarin sodium
|
ADVISE
|
Heparin_ddi.xml
|
DDI-DrugBank.d488.s1
|
DDI-DrugBank.d488.s1.p1
|
Effects of Other Antiepileptic Drugs on Felbatol Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol (felbamate) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol as compared to the same dose of Felbatol given as monotherapy.
|
Phenytoin
|
Phenytoin
|
NONE
|
Felbamate_ddi.xml
|
DDI-DrugBank.d434.s30
|
DDI-DrugBank.d434.s30.p15
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.